Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
148
-
Total 13F shares, excl. options
-
13.2M
-
Shares change
-
+595K
-
Total reported value, excl. options
-
$399M
-
Value change
-
+$13.1M
-
Put/Call ratio
-
1.67
-
Number of buys
-
88
-
Number of sells
-
-53
-
Price
-
$30.24
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q1 2019
178 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q1 2019.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.2M shares
of 14.4M outstanding shares and own 91.51% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.13M shares), KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (1.59M shares), DIMENSIONAL FUND ADVISORS LP (1.02M shares), VANGUARD GROUP INC (913K shares), STATE STREET CORP (730K shares), AMERIPRISE FINANCIAL INC (644K shares), RENAISSANCE TECHNOLOGIES LLC (365K shares), D. E. Shaw & Co., Inc. (312K shares), BTIM Corp. (264K shares), and Bank of New York Mellon Corp (259K shares).
This table shows the top 148 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.